Fernandez Antonio, Vermeren Matthieu, Humphries Duncan, Subiros-Funosas Ramon, Barth Nicole, Campana Lara, MacKinnon Alison, Feng Yi, Vendrell Marc
MRC/UoE Centre for Inflammation Research, Queen's Medical Research Institute, The University of Edinburgh, 47 Little France Crescent, EH16 4TJ Edinburgh, United Kingdom.
MRC Centre for Regenerative Medicine, SCRM Building, The University of Edinburgh, 5 Little France Drive, Edinburgh EH16 4UU, United Kingdom.
ACS Cent Sci. 2017 Sep 27;3(9):995-1005. doi: 10.1021/acscentsci.7b00262. Epub 2017 Aug 30.
Immunomodulatory agents represent one of the most promising strategies for enhancing tissue regeneration without the side effects of traditional drug-based therapies. Tissue repair depends largely on macrophages, making them ideal targets for proregenerative therapies. However, given the multiple roles of macrophages in tissue homeostasis, small molecule drugs must be only active in very specific subpopulations. In this work, we have developed the first prodrug-fluorophore conjugates able to discriminate closely related subpopulations of macrophages (i.e., proinflammatory M1 vs anti-inflammatory M2 macrophages), and employed them to deplete M1 macrophages without affecting other cell populations. Selective intracellular activation and drug release enabled simultaneous fluorescence cell tracking and ablation of M1 macrophages , with the concomitant rescue of a proregenerative phenotype. assays in human monocyte-derived macrophages validate the translational potential of this novel platform to develop chemical immunomodulatory agents as targeted therapies for immune-related diseases.
免疫调节药物是增强组织再生且无传统药物疗法副作用的最具前景的策略之一。组织修复在很大程度上依赖巨噬细胞,这使其成为促再生疗法的理想靶点。然而,鉴于巨噬细胞在组织稳态中的多种作用,小分子药物必须仅在非常特定的亚群中具有活性。在这项工作中,我们开发了第一种能够区分密切相关的巨噬细胞亚群(即促炎M1巨噬细胞与抗炎M2巨噬细胞)的前药-荧光团缀合物,并利用它们耗尽M1巨噬细胞而不影响其他细胞群体。选择性细胞内激活和药物释放能够同时进行荧光细胞追踪和M1巨噬细胞消融,并伴随促再生表型的恢复。在人单核细胞衍生巨噬细胞中的实验验证了这个新平台开发化学免疫调节药物作为免疫相关疾病靶向疗法的转化潜力。